J&J ends hepatitis B and HPV portions of Bavarian Nordic collab
Johnson & Johnson’s Janssen ended its collaboration and licensing agreements with Bavarian Nordic concerning vaccines for hepatitis B virus and human papillomaviruses.
J&J and the Danish vaccines biotech will continue their tie-up as it relates to HIV and Ebola, Janssen said Monday. The duo announced the HPV pact in December 2015 at a total potential value of $171 million, and the hepatitis B and HIV work came via a July 2017 agreement worth up to $879 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.